NCT04605796已完成2 期
A Single-arm, Open-label, Multi-center Phase II Clinical Study to Evaluate the Safety and Efficacy of Toripalimab Injection (JS001) Combined With Bevacizumab as the First-line Therapy for Advanced Hepatocellular Carcinoma (HCC)
Shanghai Junshi Bioscience Co., Ltd.1 个研究点 分布在 1 个国家目标入组 54 人开始时间: 2020年4月10日最近更新:
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 54
- 试验地点
- 1
- 主要终点
- ORR
研究概览
简要总结
This is an open-label, single-arm, national multicenter phase II clinical study to preliminarily observe and evaluate the efficacy and safety of Toripalimab combined with Bevacizumab as the first-line therapy for advanced HCC The study will use safety/tolerability and ORR as the primary study objectives and indicators, and plans to enroll about 50-60 patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •can be enrolled in this study:
- •Age of 18-70 years (inclusive), male or female.
- •HCC diagnosed by histopathological examination or Guidelines for Diagnosis and Treatment of Primary Liver Cancer (2017 Edition).
- •Stage B (middle stage) or C (late stage) HCC determined in accordance with Barcelona Clinic Liver Cancer staging system (BCLC stage). In case of stage B, the patient must be unsuitable for surgery and/or local therapy, or have progressive disease after surgery and/or local therapy, or refuse surgery and/or local therapy (special instruction and signature required).
- •No previous use of any systemic therapy or HCC.
- •Having ≥ 1 measurable lesion in accordance with RECISTv1.
- •Grade A Child-Pugh hepatic function, with no history of hepatic encephalopathy.
- •Eastern Cooperative Oncology Group Performance Status (ECOG PS) score 0-
- •Expected survival ≥12 weeks.
- •Adequate hematologic and end-organ function..
- •In case of HBsAg (+) and/or HBcAb (+), HBV DNA is required to be < 500 IU/mL, and it is required to continue the effective anti-HBV therapy that has been adopted in the full course, or start to use Entecavir or tenofovir in the full course during the study. HBV/HCV co-infected patients will be excluded. Patients with a history of HCV infection but with negative HCV RNA PCR results can be considered uninfected with HCV.
- •Female patients of childbearing potential must receive serum pregnancy test within 7 days before enrollment, have negative result, and agree to use reliable and effective contraceptive methods during the trial and within 60 days after the last dose of study drug. The male patients whose partners are women of childbearing potential must agree to use reliable and effective contraceptive methods during the trial and within 60 days after the last dose of study drug.
- •Being voluntary to participate in the study, sufficiently informed consent and signature of written informed consent form, with good compliance.
- •Patients can not be enrolled in the study if any one of the following criteria is fulfilled:
- •Known cholangiocellular carcinoma (ICC) or mixed hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma and hepatic fibrolamellar carcinoma.
- •Malignant tumor except HCC in the past 5 years: however, localized tumor cured in the study is excluded, including cervical carcinoma in situ, skin basal cell carcinoma and carcinoma in situ of prostate.
- •Hepatic surgery and/or local therapy or treatment with investigational product for HCC within 4 weeks prior to enrollment; palliative therapy for bone metastatic lesion within 2 weeks prior to enrollment. Toxicity reaction induced by previous therapy (except alopecia) not recovered to ≤ grade 1 (NCI-CTCAE v5.0). Chinese medicine preparation with anti-liver cancer effect within 2 weeks prior to enrollment.
- •Uncontrolled pericardial effusion, uncontrolled pleural effusion or clinically obvious moderate peritoneal effusion at screening,
- •History of gastrointestinal hemorrhage within 6 months prior to enrollment; the patients with portal hypertension need to receive gastroscopy to exclude the patients with "red sign", if they are considered by investigators to have high risk for hemorrhage . The patient needs to be excluded if there is a history of "red sign" in gastroscopy.
- •Having ≥ grade 3 (NCI-CTCAE v5.0) gastrointestinal or non-gastrointestinal fistula at present.
- •Patients with cancer thrombus in the main trunk of portal vein (Vp4), or cancer thrombus in inferior vena cava should be excluded. However, the patients with cancer thrombus in the main trunk of portal vein but unobstructed branch of contralateral portal vein are allowed to be enrolled.
- •Previous history of serious cardiovascular and cerebrovascular diseases:
- •Having major bleeding and coagulation disorders or other obvious evidence on hemorrhagic tendency:
- •Medium to large surgical treatment within 4 weeks prior to enrollment, however, not including diagnostic biopsy.
- •Central nervous system metastasis.
- •Serious, uncured wound, active ulcer or untreated bone fracture.
- •Vaccination of live vaccine within 30 days prior to enrollment.
- •Active autoimmune diseases requiring systemic treatment (i.e., immunomodulatory drug, corticosteroid or immunosuppressant) in the past 2 years; however, replacement therapy (e.g., thyroxine, insulin or physiological corticosteroid replacement therapy for renal or pituitary insufficiency) will not be considered as systemic therapy and is allowed to be used, and enrollment is allowed.
- •History of clear interstitial lung disease or non-infectious pneumonia, unless induced by local radiotherapy; history of active tuberculosis.
- •Any serious acute and chronic infection requiring systemic antibacterial, antifungal or antiviral therapy at screening, not including viral hepatitis.
- •Known history of human immunodeficiency virus (HIV) infection.
- •Previously receiving allogeneic stem cell or solid organ transplantation.
- •20. Known history of serious allergy to any monoclonal antibody, anti-angiogenesis targeted drug.
排除标准
- 未提供
研究组 & 干预措施
Single Arm
Experimental
Experimental group:
Toripalimab combined with Bevacizumab
干预措施: Toripalimab combined with Bevacizumab (Combination Product)
结局指标
主要结局
ORR
时间窗: Up to 2 years
The rate of participants that achieve either a complete response (CR) or a partial response (PR).
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]
时间窗: Up to 2 years
Frequency table will be used to summarize occurrence of each treatment-emergent AE
次要结局
- Overall survival (OS)(Up to 2 years)
- TTP(Up to 2 years)
- PFS(Up to 2 years)
- DoR(Up to 2 years)
- DCR(Up to 2 years)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
An Observational Real World Study on the Efficacy and Safety of Toripalimab Injection Combined With TACE in the Treatment of Extrahepatic CholangiocarcinomaExtrahepatic CholangiocarcinomaNCT05448183Xuhua Duan45
尚未招募
2 期
Nab-paclitaxel in Combination With Pyrotinib in Postoperative Adjuvant Therapy for HER2-positive Breast CancerEarly Breast CancerNCT04659499Peking Union Medical College Hospital261
撤回
2 期
A Trial of Famitinib in Patients With Failure of First-Line Treatment For Intrahepatic CholangiocarcinomaIntrahepatic CholangiocarcinomaNCT04479904Jiangsu HengRui Medicine Co., Ltd.
Unknown
2 期
Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast CancerHER2-negative Breast CancerNCT04624711The First Affiliated Hospital with Nanjing Medical University40
Unknown
2 期
A Phase II Study to Evaluate the Efficacy and Safety of F520 Combined With F007 in Patients With RR DLBCLRR DLBCL; PD-1; CD20NCT05178836Shandong New Time Pharmaceutical Co., LTD62